

Author Index

Aduma, P.J., Gupta, S.V., Stuart, A.L. and Tourigny, G., Regulatory effects of deoxyribonucleosides on the activity of 5-methoxymethyl-2'-deoxycytidine: modulation of antipheres activity by deoxyguanosine and tetrahydrodeoxyuridine, 301

Åkerfeldt, S., see Harmenberg, J., 193

Åkesson-Johansson, A., see Harmenberg, J., 193

Alin, P., see Cheetham, B.F., 27

Baba, M., see Ito, M., 323

Barnett, B.B., Burns, III, N.J., Park, K.J., Dawson, M.I., Kende, M. and Sidwell, R.W., Antiviral immunotoxins: antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro, 125

Bergman, J., see Harmenberg, J., 193

Bernstein, D.I., see Harrison, C.J., 315

Bourke, P., see Cheetham, B.F., 27

Brinton, M.A., see Morahan, P.S., 241

Broen, J.J., see Cafruny, W.A., 77

Burger, R.A., see Mead, J.R., 331

Burger, R.A., see Morrey, J.D., 51

Burns, III, N.J., see Barnett, B.B., 125

Cafruny, W.A., DesJarlais, S.E., Hecht, M.L., Broen, J.J. and Jaqua, R.A., Enhancement of murine susceptibility to oral lactate dehydrogenase-elevating virus infection by non-steroidal anti-inflammatory agents, and antagonism by misoprostol, 77

Cameron, J.M., see Coates, J.A.V., 161

Cheetham, B.F., McInnes, B., Mantamadiotis, T., Murray, P.J., Alin, P., Bourke, P., Linnane, A.W. and Tymms, M.J., Structure-function studies of human interferons: enhanced activity on human and murine cells, 27

Chirigos, M.A., see Morrey, J.D., 51

Coates, J.A.V., Ingall, H.J., Pearson, B.A., Penn, C.R., Storer, R., Williamson, C. and Cameron, J.M., Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro, 161

Coen, D.M., The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy, 287

Coombs, J., see Mead, J.R., 331

Cox, S., see Harmenberg, J., 193

Dawson, M.I., see Barnett, B.B., 125

De Clercq, E., see Ito, M., 323

DesJarlais, S.E., see Cafruny, W.A., 77

Devine, K.G., see McGuigan, C., 255

Ellis, M.N., see Lobe, D.C., 87

Endo, T., see Higuchi, H., 205

Garcia-Villalón, D. and Gill-Fernández, C., Antiviral activity of sulfated polysaccharides against African swine fever virus, 139

Gardner, M.B., Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents, 267

Gessaman, A.C., see Smee, D.F., 229

Gill-Fernández, C., see Garcia-Villalón, D., 139

Goshima, F., see Yamada, Y., 171

Griffin, D.E., Therapy of viral infections of the central nervous system, 1

Gräslund, A., see Harmenberg, J., 193

Gupta, S.V., see Aduma, P.J., 301

Harada, H., Sakagami, H., Nagata, K., Oh-hara, T., Kawazoe, Y., Ishihama, A., Hata, N., Misawa, Y., Terada, H. and Konno, K., Possible involvement of lignin structure in anti-influenza virus activity, 41

Harmenberg, J., Åkesson-Johansson, A., Gräslund, A., Malmfors, T., Bergman, J., Wahren, B., Åkerfeldt, S., Lundblad, L. and Cox, S., The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-d)quinoxaline, 193

Harrison, C.J., Stanberry, L.R. and Bernstein, D.I., Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs, 315

Hata, N., see Harada, H., 41

Hecht, M.L., see Cafruny, W.A., 77

Helmy, M.F., see Upadhyay, J.M., 67

Higuchi, H., Mori, K., Kato, A., Ohkuma, T., Endo, T., Kaji, H. and Kaji, A., Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase, 205

Hill, J.M., see Upadhyay, J.M., 67

Hudson, J.B., Lopez-Bazzocchi, I. and Towers, G.H.N., Antiviral activities of hypericin, 101

Huffman, J.H., see Smee, D.F., 229

Huggins, J., see Mead, J.R., 331

Huggins, J.W., see Smee, D.F., 229

Ihara, T., see Ito, M., 183

Ingall, H.J., see Coates, J.A.V., 161
 Inouye, Y., see Take, Y., 113
 Ishihama, A., see Harada, H., 41
 Ito, M., Baba, M., Shigeta, S., De Clercq, E., Walker, R.T., Tanaka, H. and Miyasaka, T., Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenyl-thiouridine (HEPT) and recombinant alpha interferon, 323
 Ito, M., Nakano, T., Kamiya, T., Kitamura, K., Ihara, T., Kamiya, H. and Sakurai, M., Effects of tumor necrosis factor alpha on replication of varicella-zoster virus, 183
 Jaqua, R.A., see Cafruny, W.A., 77
 Jemison, M., see Upadhyay, J.M., 67
 Kaji, A., see Higuchi, H., 205
 Kaji, H., see Higuchi, H., 205
 Kamiya, H., see Ito, M., 183
 Kamiya, T., see Ito, M., 183
 Kato, A., see Higuchi, H., 205
 Kaufman, H.E., see Upadhyay, J.M., 67
 Kawazoe, Y., see Harada, H., 41
 Kende, M., see Barnett, B.B., 125
 Kende, M., see Mead, J.R., 331
 Kinchington, D., see McGuigan, C., 255
 Kitamura, K., see Ito, M., 183
 Konno, K., see Harada, H., 41
 Korba, B.E. and Milman, G., A cell culture assay for compounds which inhibit hepatitis B virus replication, 217
 Kurokawa, M., see Ochiai, H., 149
 Linnane, A.W., see Cheetham, B.F., 27
 Lobe, D.C., Spector, T. and Ellis, M.N., Synergistic topical therapy by acyclovir and A111OU for herpes simplex virus induced zosteriform rash in mice, 87
 Lopez-Bazzocchi, I., see Hudson, J.B., 101
 Lundblad, L., see Harmenberg, J., 193
 Malmfors, T., see Harmenberg, J., 193
 Mantamadiotis, T., see Cheetham, B.F., 27
 McGuigan, C., Devine, K.G., O'Connor, T.J. and Kinchington, D., Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT): potent activity of the trichloroethyl methoxyalaninyl compound, 255
 McInnes, B., see Cheetham, B.F., 27
 Mead, J.R., Burger, R.A., Yonk, L.J., Coombs, J., Warren, R.P., Kende, M., Huggins, J. and Sidwell, R.W., Effect of human, recombinant interleukin 2 on Punta Toro virus infections in C57BL/6 mice, 331
 Milman, G., see Korba, B.E., 217
 Misawa, Y., see Harada, H., 41
 Miyasaka, T., see Ito, M., 323
 Montefiori, D.C. and Zhou, J., Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro, 11
 Morahan, P.S., Pinto, A., Stewart, D., Murasko, D.M. and Brinton, M.A., Varying role of alpha/beta interferon in the antiviral efficacy of synthetic immunomodulators against Semliki Forest virus infection, 241
 Mori, K., see Higuchi, H., 205
 Morrey, J.D., Warren, R.P., Okleberry, K.M., Burger, R.A., Chirigos, M.A. and Sidwell, R.W., Effect of imexon treatment on Friend virus complex infection using genetically defined mice as a model for HIV-1 infection, 51
 Murasko, D.M., see Morahan, P.S., 241
 Murray, P.J., see Cheetham, B.F., 27
 Myers, M.G. and Stanberry, L.R., Drug testing for activity against varicella-zoster virus in hairless guinea pigs, 341
 Nagata, K., see Harada, H., 41
 Nakamura, S., see Take, Y., 113
 Nakano, T., see Ito, M., 183
 Nishiyama, Y., see Yamada, Y., 171
 Niwayama, S., see Ochiai, H., 149
 O'Connor, T.J., see McGuigan, C., 255
 Ochiai, H., Kurokawa, M. and Niwayama, S., Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells, 149
 Oh-hara, T., see Harada, H., 41
 Okhuma, T., see Higuchi, H., 205
 Okleberry, K.M., see Morrey, J.D., 51
 Park, K.J., see Barnett, B.B., 125
 Pearson, B.A., see Coates, J.A.V., 161
 Penn, C.R., see Coates, J.A.V., 161
 Pinto, A., see Morahan, P.S., 241
 Sakagami, H., see Harada, H., 41
 Sakurai, M., see Ito, M., 183
 Shigeta, S., see Ito, M., 323
 Shimokata, K., see Yamada, Y., 171
 Sidwell, R.W., see Barnett, B.B., 125
 Sidwell, R.W., see Mead, J.R., 331
 Sidwell, R.W., see Morrey, J.D., 51
 Sidwell, R.W., see Smee, D.F., 229
 Smee, D.F., Huffman, J.H., Gessaman, A.C., Huggins, J.W. and Sidwell, R.W., Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice, 229

Spector, T., see Lobe, D.C., 87
Stanberry, L.R., see Harrison, C.J., 315
Stanberry, L.R., see Myers, M.G., 341
Stewart, D., see Morahan, P.S., 241
Storer, R., see Coates, J.A.V., 161
Stuart, A.L., see Aduma, P.J., 301


Take, Y., Tokutake, Y., Inouye, Y., Yoshida, T., Yamamoto, A., Yamase, T. and Nakamura, S., Inhibition of proliferation of human immunodeficiency virus type 1 by novel heteropolyoxotungstates in vitro, 113
Tanaka, H., see Ito, M., 323
Terada, H., see Harada, H., 41
Tokutake, Y., see Take, Y., 113
Tourigny, G., see Aduma, P.J., 301
Towers, G.H.N., see Hudson, J.B., 101
Tymms, M.J., see Cheetham, B.F., 27

Upadhyay, J.M., Hill, J.M., Jemison, M., Helmy, M.F. and Kaufman, H.E., The effect of HSV multiplica-
tion rate on antiviral drug efficacy in vitro, 67

Wahren, B., see Harmenberg, J., 193
Walker, R.T., see Ito, M., 323
Warren, R.P., see Mead, J.R., 331
Warren, R.P., see Morrey, J.D., 51
Williamson, C., see Coates, J.A.V., 161

Yamada, Y., Shimokata, K., Yamada, Y., Yamamoto, N., Goshima, F. and Nishiyama, Y., Inhibition of influenza A virus replication by a kanamycin derivative, 171
Yamada, Y., see Yamada, Y., 171
Yamamoto, A., see Take, Y., 113
Yamamoto, N., see Yamada, Y., 171
Yamase, T., see Take, Y., 113
Yonk, L.J., see Mead, J.R., 331
Yoshida, T., see Take, Y., 113

Zhou, J., see Montefiori, D.C., 11



Subject Index

A111OU, Herpes simplex virus, Murine zosteriform rash model, Acyclovir, Synergistic topical therapy, Ribonucleotide reductase, 87

ABMP, Interferon, MVE-2, Ampligen, CL246,738, Poly ICLC, Semliki Forest virus, Anti-interferon serum, 242

AIDS, Carbovir, Nucleoside, HIV, 161

AIDS, IFN- α , Synergistic inhibition, 323

AIDS, Imexon, HIV-1, Friend virus, Model, Genetically, 51

Acquired immune deficiency syndrome, Melanin, Antiviral therapy, 11

Acyclovir, Herpes simplex virus, Murine zosteriform rash model, A111OU, Synergistic topical therapy, Ribonucleotide reductase, 87

Acyclovir, Varicella, Antiviral testing, Animal model, Guinea pig, 6-Methoxypurine arabinoside, 341

Aerosol treatment, Kanamycin derivative, Influenza virus, Lysosomal pH, 171

African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, Heparin, 139

Alizarin complexone, Reverse transcriptase, Retrovirus, 205

Ampligen, Interferon, MVE-2, CL246,738, Poly ICLC, ABMP, Semliki Forest virus, Anti-interferon serum, 242

Animal model, Varicella, Antiviral testing, Guinea pig, Acyclovir, 6-Methoxypurine arabinoside, 341

Anti-AIDS, Nucleoside analog, Nucleotide ester, Anti-HIV, Phosphoramidate, 255

Anti-HIV, Nucleoside analog, Nucleotide ester, Anti-AIDS, Phosphoramidate, 255

Anti-interferon serum, Interferon, MVE-2, Ampligen, CL246,738, Poly ICLC, ABMP, Semliki Forest virus, 242

Antiherpes activity, 5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Deoxyguanosine potentiation, dNTP pool, HSV-infected cell, 301

Antiviral therapy, Melanin, Acquired immune deficiency syndrome, 11

Antiviral drug, Herpesvirus, Drug resistance, Nucleoside analog, 287

Antiviral testing, Varicella, Animal model, Guinea pig, Acyclovir, 6-Methoxypurine arabinoside, 341

Antiviral, HSV-1, In vitro, Stromal disease, Viral replication, 67

Antiviral, Immunotoxin, Gelonin, Pichinde virus, Arenavirus, Targeted delivery, 125

Arenavirus, Immunotoxin, Gelonin, Pichinde virus, Antiviral, Targeted delivery, 125

Biologic response modifier, R-837, Recurrent genital herpes, IL-2, Interferon, UV radiation, 315

Bunyaaviridae, Punta Toro virus, Phlebovirus, Interleukin 2, Immune response, 331

CL246,738, Interferon, MVE-2, Ampligen, Poly ICLC, ABMP, Semliki Forest virus, Anti-interferon serum, 242

Calmodulin, Trifluoperazine, Influenza virus, Morphogenesis, 149

Carbovir, Nucleoside, HIV, AIDS, 161

Cell culture assay, Hepatitis B virus, 217

Deoxyguanosine potentiation, 5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, dNTP pool, HSV-infected cell, 301

Dextran sulfate, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Heparin, 139

dNTP pool, 5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Deoxyguanosine potentiation, Antiherpes activity, HSV-infected cell, 301

Drug resistance, Antiviral drug, Herpesvirus, Nucleoside analog, 287

Feline immunodeficiency virus, Simian immunodeficiency virus, Lentivirus, Vaccine, 267

Friend virus, Imexon, AIDS, HIV-1, Model, Genetically, 51

Fucoidan, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Dextran sulfate, Heparin, 139

Gelonin, Immunotoxin, Pichinde virus, Antiviral, Arenavirus, Targeted delivery, 125

Genetically, Imexon, AIDS, HIV-1, Friend virus, Model, 51

Guinea pig, Varicella, Antiviral testing, Animal model, Acyclovir, 6-Methoxypurine arabinoside, 341

HIV, Carbovir, Nucleoside, AIDS, 161

HIV-1, Imexon, AIDS, Friend virus, Model, Genetically, 51

HSV-1, Antiviral, In vitro, Stromal disease, Viral replication, 67

HSV-infected cell, 5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Deoxyguanosine potentiation, Antiherpes activity, dNTP pool, 301

Heparin, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, 139

Hepatitis B virus, Cell culture assay, 217

Herpes simplex virus, Murine zosteriform rash model, A111OU, Acyclovir, Synergistic topical therapy, Ribonucleotide reductase, 87

Herpes simplex virus, Indoloquinoxaline, Uncoating, 193

Herpesvirus, Antiviral drug, Drug resistance, Nucleoside analog, 287

Heteropolyoxotungstate, PM-19, Kegg structure, Human immunodeficiency virus type 1, 113

Human immunodeficiency virus type 1, Heteropolyoxotungstate, PM-19, Kegg structure, 113

Hypericin, Photosensitization, 101

IFN- α , AIDS, Synergistic inhibition, 323

IL-2, R-837, Recurrent genital herpes, Biologic response modifier, Interferon, UV radiation, 315

Imexon, AIDS, HIV-1, Friend virus, Model, Genetically, 51

Immune response, Punta Toro virus, Phlebovirus, Bunyaviridae, Interleukin 2, 331

Immunotoxin, Gelonin, Pichinde virus, Antiviral, Arenavirus, Targeted delivery, 125

In vitro, Antiviral, HSV-1, Stromal disease, Viral replication, 67

Indoloquinoxaline, Herpes simplex virus, Uncoating, 193

Influenza virus, Lignin, 41

Influenza virus, Trifluoperazine, Calmodulin, Morphogenesis, 149

Influenza virus, Kanamycin derivative, Lysosomal pH, Aerosol treatment, 171

Interferon, IFN, Tumor necrosis factor, TNF, Varicella-zoster virus, VZV, 183

Interferon inducer, Phlebovirus, Nucleoside, 229

Interferon, MVE-2, Ampligen, CL246,738, Poly ICLC, ABMP, Semliki Forest virus, Anti-interferon serum, 242

Interferon, R-837, Recurrent genital herpes, Biologic response modifier, IL-2, UV radiation, 315

Interleukin 2, Punta Toro virus, Phlebovirus, Bunya-
viridae, Immune response, 331

Kanamycin derivative, Influenza virus, Lysosomal pH, Aerosol treatment, 171

Kappa carrageenan, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, Heparin, 139

Kegg structure, Heteropolyoxotungstate, PM-19, Human immunodeficiency virus type 1, 113

Lambda carrageenan, African swine fever virus, Sulfated polysaccharide, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, Heparin, 139

Lentivirus, Simian immunodeficiency virus, Feline immunodeficiency virus, Vaccine, 267

Lignin, Influenza virus, 41

Lysosomal pH, Kanamycin derivative, Influenza virus, Aerosol treatment, 171

MVE-2, Interferon, Ampligen, CL246,738, Poly ICLC, ABMP, Semliki Forest virus, Anti-interferon serum, 242

Melanin, Antiviral therapy, Acquired immune deficiency syndrome, 11

5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Deoxyguanosine potentiation, Antiherpes activity, dNTP pool, HSV-infected cell, 301

6-Methoxypurine arabinoside, Varicella, Antiviral testing, Animal model, Guinea pig, Acyclovir, 341

Misoprostol, Virus infection, Mucosal barrier, NSAIDs, 77

Model, Imexon, AIDS, HIV-1, Friend virus, Genetically, 51

Morphogenesis, Trifluoperazine, Calmodulin, Influenza virus, 149

Mucosal barrier, Virus infection, Misoprostol, NSAIDs, 77

Murine zosteriform rash model, Herpes simplex virus, A111OU, Acyclovir, Synergistic topical therapy, Ribonucleotide reductase, 87

NSAIDs, Virus infection, Mucosal barrier, Misoprostol, 77

Nucleoside, Carbovir, HIV, AIDS, 161

Nucleoside, Phlebovirus, Interferon inducer, 229

Nucleoside analog, Nucleotide ester, Anti-HIV, Anti-AIDS, Phosphoramidate, 255

Nucleoside analog, Antiviral drug, Herpesvirus, Drug resistance, 287

Nucleotide ester, Nucleoside analog, Anti-HIV, Anti-AIDS, Phosphoramidate, 255

PM-19, Heteropolyoxotungstate, Keggin structure, Human immunodeficiency virus type 1, 113

Pentosan polysulfate, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Fucoidan, Dextran sulfate, Heparin, 139

Phlebovirus, Nucleoside, Interferon inducer, 229

Phlebovirus, Punta Toro virus, Bunyaviridae, Interleukin 2, Immune response, 331

Phosphoramidate, Nucleoside analog, Nucleotide ester, Anti-HIV, Anti-AIDS, 255

Photosensitization, Hypericin, 101

Pichinde virus, Immunotoxin, Gelonin, Antiviral, Arenavirus, Targeted delivery, 125

Poly ICLC, Interferon, MVE-2, Ampligen, CL246,738, ABMP, Semliki Forest virus, Anti-interferon serum, 242

Punta Toro virus, Phlebovirus, Bunyaviridae, Interleukin 2, Immune response, 331

R-837, Recurrent genital herpes, Biologic response modifier, IL-2, Interferon, UV radiation, 315

Recurrent genital herpes, R-837, Biologic response modifier, IL-2, Interferon, UV radiation, 315

Retrovirus, Alizarin complexone, Reverse transcriptase, 205

Reverse transcriptase, Alizarin complexone, Retrovirus, 205

Ribonucleotide reductase, Herpes simplex virus, Murine zosteriform rash model, A111OU, Acyclovir, Synergistic topical therapy, 87

Semliki Forest virus, Interferon, MVE-2, Ampligen, CL246,738, Poly ICLC, ABMP, Anti-interferon serum, 242

Simian immunodeficiency virus, Feline immunodeficiency virus, Lentivirus, Vaccine, 267

Stromal disease, Antiviral, HSV-1, In vitro, Viral replication, 67

Sulfated polysaccharide, African swine fever virus, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, Heparin, 139

Synergistic topical therapy, Herpes simplex virus, Murine zosteriform rash model, A111OU, Acyclovir, Ribonucleotide reductase, 87

Synergistic inhibition, IFN- α , AIDS, 323

Targeted delivery, Immunotoxin, Gelonin, Pichinde virus, Antiviral, Arenavirus, 125

Tetrahydrodeoxyuridine (deaminase inhibitor), 5-Methoxymethyl-2'-deoxycytidine, Deoxyguanosine potentiation, Ant herpes activity, dNTP pool, HSV-infected cell, 301

Trifluoperazine, Calmodulin, Influenza virus, Morphogenesis, 149

Tumor necrosis factor, TNF, Varicella-zoster virus, VZV, Interferon, IFN, 183

UV radiation, R-837, Recurrent genital herpes, Biologic response modifier, IL-2, Interferon, 315

Uncoating, Herpes simplex virus, Indoloquinoxaline, 193

Vaccine, Simian immunodeficiency virus, Feline immunodeficiency virus, Lentivirus, 267

Varicella, Antiviral testing, Animal model, Guinea pig, Acyclovir, 6-Methoxypurine arabinoside, 341

Varicella-zoster virus, VZV, Tumor necrosis factor, TNF, Interferon, IFN, 183

Viral replication, Antiviral, HSV-1, In vitro, Stromal disease, 67

Virus infection, Mucosal barrier, Misoprostol, NSAIDs, 77